171 related articles for article (PubMed ID: 34328338)
1. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
3. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
4. Development of
Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
[TBL] [Abstract][Full Text] [Related]
5. Detection of HER2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of
Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V
Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776
[TBL] [Abstract][Full Text] [Related]
7.
Altunay B; Goedicke A; Winz OH; Hertel F; von Mallek D; Meszaros LK; Chand G; Biersack HJ; Stickeler E; Krauss K; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1005-1013. PubMed ID: 36482076
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
[TBL] [Abstract][Full Text] [Related]
9. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of
Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging of HER2 Expression in Breast Cancer patients Using the [
Biabani Ardakani J; Abedi SM; Mardanshahi A; Shojaee L; Zaboli E; Khorramimoghaddam A; Nosrati A; Sabahno H; Banimostafavi ES; Hosseinimehr SJ
Clin Breast Cancer; 2023 Feb; 23(2):219-230. PubMed ID: 36581518
[TBL] [Abstract][Full Text] [Related]
12. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
13. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
14. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
15. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
[TBL] [Abstract][Full Text] [Related]
16. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
17. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
18. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
[TBL] [Abstract][Full Text] [Related]
19. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
